CN117747100B - System for predicting occurrence risk of obstructive sleep apnea - Google Patents
System for predicting occurrence risk of obstructive sleep apnea Download PDFInfo
- Publication number
- CN117747100B CN117747100B CN202311686767.XA CN202311686767A CN117747100B CN 117747100 B CN117747100 B CN 117747100B CN 202311686767 A CN202311686767 A CN 202311686767A CN 117747100 B CN117747100 B CN 117747100B
- Authority
- CN
- China
- Prior art keywords
- scoring
- sleep apnea
- obstructive sleep
- risk
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001797 obstructive sleep apnea Diseases 0.000 title claims abstract description 219
- 150000001413 amino acids Chemical class 0.000 claims abstract description 145
- 230000000694 effects Effects 0.000 claims abstract description 45
- 238000004458 analytical method Methods 0.000 claims abstract description 43
- 230000009471 action Effects 0.000 claims abstract description 15
- 239000000090 biomarker Substances 0.000 claims abstract description 8
- 238000004590 computer program Methods 0.000 claims abstract description 8
- 229940024606 amino acid Drugs 0.000 claims description 140
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 55
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 29
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 29
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 29
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 29
- 229960000310 isoleucine Drugs 0.000 claims description 29
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 29
- 239000004474 valine Substances 0.000 claims description 29
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 28
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 28
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 28
- 239000004471 Glycine Substances 0.000 claims description 27
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 27
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 16
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 abstract description 32
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 128
- 230000002829 reductive effect Effects 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 12
- 230000036541 health Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000004280 healthy diet Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XHXXVVZZZPRJNS-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;lead Chemical compound [Pb].OC(=O)[C@@H](N)CC1=CC=CC=C1 XHXXVVZZZPRJNS-QRPNPIFTSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
The invention relates to the field of digital medical technology, a system for predicting the risk of occurrence of obstructive sleep apnea, a computer readable storage medium storing a computer program comprising program instructions which, when executed by a processor, cause the processor to perform the steps of: acquiring prediction data of occurrence risk of obstructive sleep apnea; performing high-throughput metabolism biomarker analysis on the predicted data to obtain the blood plasma amino acid level; analyzing the influence relation between different amino acid levels and the risk of obstructive sleep apnea based on the blood plasma amino acid levels, and selecting a plurality of amino acids as scoring parameters according to the influence relation; analyzing the effect of the scoring parameter on the obstructive sleep apnea risk according to the influence relation; setting a horizontal interval of a scoring parameter according to the action effect, scoring the amino acid level of the individual, and predicting the occurrence risk of obstructive sleep apnea.
Description
Technical Field
The invention relates to the technical field of digital medical treatment, in particular to a system for predicting the occurrence risk of obstructive sleep apnea.
Background
Obstructive sleep apnea is a serious sleep disorder affecting hundreds of millions of adults worldwide. The disease is characterized in that respiratory tract is repeatedly blocked in sleep, so that the respiratory tract is in apnea and hypopnea, and the symptoms such as snoring, nocturnal asphyxia feeling or suffocation are mainly represented. Although obstructive sleep apnea is prevalent, many patients are not diagnosed due to inadequate awareness. OSA will cause a range of health problems including cardiovascular and cerebrovascular diseases, psychological disorders, neurological impairment, social confusion, and the like. Thus, identifying high risk factors that trigger obstructive sleep apnea is critical for early risk identification and prevention.
Current studies show that poor dietary nutrition is one of the important factors in the occurrence and progression of obstructive sleep apnea. From the aspect of diet nutrition, the method can help to identify high-risk groups which are easy to suffer from obstructive sleep apnea, and has important clinical and public health significance. The protein is a nutrient substance necessary for human life activities, the main metabolic component of the protein is amino acid, different types of amino acids have different physiological functions, different degrees of influence on the occurrence of obstructive sleep apnea are generated, and a prediction system for the occurrence risk of obstructive sleep apnea is needed to predict the risk coefficient of obstructive sleep apnea based on the influence condition of different amino acids.
Disclosure of Invention
In view of the shortcomings of the prior art, the present invention provides, in a first aspect, a computer readable storage medium, characterized in that the computer readable storage medium stores a computer program comprising program instructions that, when executed by a processor, cause the processor to perform the steps of: acquiring predictive data of the risk of occurrence of obstructive sleep apnea, the predictive data being derived from a population not diagnosed with obstructive sleep apnea; performing high-throughput metabolic biomarker analysis on the predicted data to obtain plasma amino acid levels; analyzing influence relations between different amino acid levels and obstructive sleep apnea risks based on the plasma amino acid levels, and selecting a plurality of amino acids as scoring parameters according to the influence relations; analyzing the effect of the scoring parameter on the risk of obstructive sleep apnea according to the influence relation; and setting a horizontal interval of a scoring parameter according to the action effect, scoring the individual amino acid level based on the horizontal interval, and predicting the occurrence risk of obstructive sleep apnea. The invention predicts the risk of obstructive sleep apnea by using the amino acid combination marker, provides a new and important supplementary detection method, can more accurately evaluate and manage the risk of obstructive sleep apnea, and has practical application value.
Optionally, the analyzing the influence relationship of different amino acid levels to the risk of obstructive sleep apnea based on the plasma amino acid levels comprises: analyzing the plasma amino acid level for a correlation with a risk of obstructive sleep apnea, the correlation comprising a positive correlation, a negative correlation, and no significant correlation; and analyzing the influence relation of different amino acid levels on the risk of obstructive sleep apnea according to the correlation. The invention explores the correlation between the blood plasma amino acid level and the risk of the new obstructive sleep apnea, and further knows the relationship between the amino acid level and the risk of the obstructive sleep apnea, thereby providing more accurate basis for prevention and treatment.
Optionally, the selecting multiple amino acids according to the influence relationship as the scoring parameters includes: selecting histidine as a first scoring parameter according to the influence relation; tyrosine is selected as a second scoring parameter according to the influence relation; selecting isoleucine as a third scoring parameter according to the influence relationship; valine is selected as a fourth scoring parameter according to the influence relation; selecting glutamine as a fifth scoring parameter according to the influence relation; glycine is selected as a sixth scoring parameter according to the influence relation; and selecting phenylalanine as a seventh scoring parameter according to the influence relation. According to the invention, various amino acids are used as scoring parameters, so that the health condition of an individual and the occurrence risk of obstructive sleep apnea can be more comprehensively evaluated, more accurate health management and preventive measures are provided, the amino acids have better specificity, the risk of obstructive sleep apnea can be more accurately predicted, and the accuracy and efficiency of prediction are improved.
Optionally, the analyzing the effect of the scoring parameter on the risk of obstructive sleep apnea according to the influence relation includes: setting analysis rules of obstructive sleep apnea risks according to the influence relation; and obtaining the effect of different amino acid levels on the risk of obstructive sleep apnea based on the analysis rule and the influence relation. The invention sets the analysis rule of the obstructive sleep apnea risk, can more accurately analyze the effect of the amino acid level on the obstructive sleep apnea risk, and improves the accuracy and efficiency of prediction.
Optionally, the setting the horizontal interval of the scoring parameter according to the action effect includes: quartering the amino acid level of the scoring parameter in combination with the scoring parameter and the effect; and setting the horizontal interval of each scoring parameter according to the result of the amino acid level quartering. The invention divides the amino acid level of the scoring parameter into four equal parts, can more intuitively know the relationship between different amino acid levels and the risk of obstructive sleep apnea, and provides a reference basis for setting a level interval.
Optionally, scoring individual amino acid levels based on the level interval and predicting the risk of occurrence of obstructive sleep apnea comprises: obtaining scoring results of each scoring parameter according to the horizontal interval and the action effect; predicting the occurrence risk of the individual obstructive sleep apnea according to the scoring result. The invention obtains the scoring result of each scoring parameter according to the horizontal interval and the action effect, can more accurately predict the occurrence risk of the individual obstructive sleep apnea, and provides more specific prevention and treatment guidance for the individual.
Optionally, the obtaining the scoring result of each scoring parameter according to the horizontal interval and the action effect includes: setting a diversity scoring model according to the scoring parameters and the horizontal interval; and obtaining the scoring result of each scoring parameter according to the diversity scoring model. According to the invention, the scoring results of each scoring parameter are obtained according to the diversity scoring model, so that the health condition and risk level of an individual can be evaluated more objectively and fairly, and the influence of main subjective factors on the evaluation results is reduced.
Optionally, the diversity scoring model satisfies the following relationship:
Wherein, Representing diversity scoring results, n representing the number of scoring parameters,/>And the scoring results of the scoring parameters are represented. According to the method, the diversity scoring result of the individual is calculated according to the standard reaching state of the scoring parameter, the model is simple and easy to understand, the diversity scoring result of the individual can be obtained rapidly, and the accuracy and the efficiency of prediction are improved.
Optionally, the diversity scoring model whereinComprising the following steps: the scoring result of the parameter is marked as 1 if the scoring parameter is not marked as 0; /(I)A scoring result representing a first scoring parameter, which meets the safety level interval of histidine and meets the/>；/>Representing the scoring result of the second scoring parameter, if the scoring result meets the safety level interval of tyrosine, the scoring parameter meets the standard/>；/>A scoring result representing a third scoring parameter that meets/>, if the score meets the safety level interval of isoleucine；/>A scoring result representing a fourth scoring parameter which meets the safety level interval of valine and meets/>；/>A scoring result representing a fifth scoring parameter, which meets the safety level interval of glutamine and meets/>；/>A scoring result representing a sixth scoring parameter, which meets the safety level interval of glycine and meets the/>；/>A scoring result representing a seventh scoring parameter, which meets the safety level interval of phenylalanine and meets/>. In another aspect, the present invention also provides a risk prediction system for obstructive sleep apnea, comprising an input device, a processor, an output device and a memory, wherein the input device, the processor, the output device and the memory are connected to each other, the memory comprises a computer readable storage medium according to the first aspect of the present invention, the memory is used for storing a computer program, the computer program comprises program instructions, and the processor is configured to invoke the program instructions. The system provided by the invention has compact structure and strong applicability, and greatly improves the operation efficiency.
Drawings
FIG. 1 is a flowchart of program instructions in a computer readable storage medium provided by the present invention;
FIG. 2 is a schematic representation of the effect of tyrosine on the risk of obstructive sleep apnea according to the present invention;
FIG. 3 is a schematic representation of the effect of isoleucine on the risk of obstructive sleep apnea according to the present invention;
FIG. 4 is a graph showing the effect of valine on risk of obstructive sleep apnea according to the present invention;
FIG. 5 is a schematic representation of the effect of phenylalanine on the risk of obstructive sleep apnea according to the present invention;
FIG. 6 is a schematic representation of the effect of histidine on risk of obstructive sleep apnea according to the present invention;
FIG. 7 is a schematic representation of the effect of glutamine on risk of obstructive sleep apnea according to the present invention;
FIG. 8 is a schematic representation of the effect of glycine on the risk of obstructive sleep apnea according to the present invention;
FIG. 9 is a schematic representation of the effect of amino acid diversity on risk of obstructive sleep apnea according to the present invention;
fig. 10 is a schematic diagram of the structure of a system of the present invention for predicting the risk of occurrence of obstructive sleep apnea.
Detailed Description
Specific embodiments of the invention will be described in detail below, it being noted that the embodiments described herein are for illustration only and are not intended to limit the invention. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be apparent to one of ordinary skill in the art that: no such specific details are necessary to practice the invention. In other instances, well-known circuits, software, or methods have not been described in detail in order not to obscure the invention.
Throughout the specification, references to "one embodiment," "an embodiment," "one example," or "an example" mean: a particular feature, structure, or characteristic described in connection with the embodiment or example is included within at least one embodiment of the invention. Thus, the appearances of the phrases "in one embodiment," "in an embodiment," "one example," or "an example" in various places throughout this specification are not necessarily all referring to the same embodiment or example. Furthermore, the particular features, structures, or characteristics may be combined in any suitable combination and/or sub-combination in one or more embodiments or examples. Moreover, those of ordinary skill in the art will appreciate that the illustrations provided herein are for illustrative purposes and that the illustrations are not necessarily drawn to scale.
Referring to fig. 1, in one embodiment, the present invention provides a computer readable storage medium storing a computer program comprising program instructions that, when executed by a processor, cause the processor to perform the steps of:
S1, obtaining prediction data of occurrence risk of obstructive sleep apnea, wherein the prediction data is derived from people who are not diagnosed with obstructive sleep apnea, and the specific implementation steps and related contents are as follows:
At baseline investigation, the population diagnosed as obstructive sleep apnea from the study or hospital was excluded and the complete amino acid data was selected for participation. In this example a total of 116539 participants were included and relevant data collected. In the embodiment, participants with complete amino acid data are selected to ensure the integrity of the predicted data, avoid the influence of data loss on analysis results, and help to improve the accuracy and reliability of data analysis. On the other hand, the method can avoid the influence of other interference factors on the prediction result by excluding the crowd diagnosed with the obstructive sleep apnea from the hospital, only acquire the data of the crowd without the obstructive sleep apnea, and can more accurately evaluate the relation between the amino acid level and the obstructive sleep apnea risk.
The collected data is then subjected to cleaning and preprocessing, including but not limited to outlier processing, missing value padding, and duplicate value deletion, to ensure the integrity and accuracy of the predicted data. The pre-processed predicted data may also be subjected to further analysis, including but not limited to correlation analysis, regression analysis, machine learning methods, using statistical methods and data analysis techniques to determine associations and effects between amino acid levels and risk of obstructive sleep apnea.
Furthermore, in this embodiment, the crowd diagnosed with obstructive sleep apnea by self-description or hospital is excluded, the influence of other factors on the prediction result can be directly avoided, the relationship between the amino acid level and the obstructive sleep apnea risk can be more accurately estimated, the collection mode and the preprocessing method of the predicted data in the embodiment are only an optional condition of this embodiment, and the collection mode of the disease risk predicted data can be changed according to the actual application requirement, so as to ensure the integrity and the accuracy of the predicted data, thereby being beneficial to promoting the development and progress of the research field of the amino acid and the obstructive sleep apnea, and providing solid data basis and scientific guidance for research and treatment.
S2, performing high-flux metabolism biomarker analysis on the predicted data to obtain the blood plasma amino acid level, wherein the specific implementation steps and related contents are as follows:
the high throughput metabolic biomarker analysis platform based on Nuclear Magnetic Resonance (NMR) was used in this example to measure individual plasma amino acid levels.
Extraction of metabolites, including but not limited to amino acids, ketone bodies, organic acids, from a participant's plasma sample requires ensuring the quality and stability of the test sample, avoiding bias and confusion of analysis results. Then, a high-flux metabolism biomarker analysis method is adopted, specifically, a liquid chromatography-mass spectrometry (LC-MS) technology can be utilized to carry out qualitative and quantitative analysis on the extracted metabolites, and based on the analysis method, various metabolites can be measured simultaneously, so that the analysis efficiency is improved, and the error probability is reduced; and finally, carrying out statistical analysis on the processed data by using statistical software, wherein the statistical analysis model is a mature modeling method in the fields of statistics and machine learning, can effectively process a plurality of prediction variables, further optimizes model parameters to comprehensively consider a plurality of factors including amino acid level, demographic characteristics, living habits and the like, improves the accuracy of the prediction results, and can more comprehensively predict the occurrence risk of obstructive sleep apnea.
In the embodiment, a high-flux metabolism biomarker analysis platform based on NMR is utilized to measure and analyze the blood plasma amino acid level, so that the relation between different amino acids and the occurrence risk of obstructive sleep apnea is further explored, and the method is beneficial to better preventing and treating the obstructive sleep apnea.
Furthermore, the high-throughput metabolism biomarker analysis platform based on NMR in this embodiment is only an optional condition of this embodiment, and the analysis technology can be modified according to the actual application requirement to ensure the integrity and accuracy of the predicted data, so as to provide solid data basis and scientific guidance for research and treatment.
For further analysis of the demographic characteristics, please refer to table 1, the average age of 116539 participants in this example was 56.5 years, with a female demographic of 53.4%. The participants cover people with different sexes, ages, race and health conditions, and have a certain representativeness. The proportion of men and caucasians is lower, the proportion of smokers and obese people is higher, and the proportion of people suffering from asthma, hypertension, diabetes and hyperlipidemia is higher than the proportion of people without obstructive sleep apnea. These factors have a certain impact on the occurrence of obstructive sleep apnea, and further discussion of the underlying causes and mechanisms is needed.
In addition, the crowd suffering from obstructive sleep apnea shows the characteristics of greater thompson deprivation index, but lower physical activity level and healthy diet index, so that the life quality and health condition of the crowd can be known, and the risk of the obstructive sleep apnea is affected to a certain extent, and particularly, please refer to table 1.
Table 1 characteristic forms of obstructive sleep apnea in a population
In this example, the predicted data mainly includes levels of amino acids such as histidine, tyrosine, isoleucine, valine, glutamine, glycine, and phenylalanine in plasma. Other relevant information of the collected individual is also collected and recorded, including but not limited to age, sex, body mass index, health meal index, and history of disease. Baseline survey data of 116539 participants was used as predictive data in this example, further revealing the relationship between amino acid levels and risk of obstructive sleep apnea. At the same time, the research results also provide deep knowledge about the crowd characteristics and related factors of the incidence risk of obstructive sleep apnea, and help to better prevent and treat obstructive sleep apnea.
In this embodiment, the analysis of the blood plasma amino acid level can detect abnormal changes related to specific diseases or pathological processes, which are earlier than other clinical symptoms, which is helpful for early diagnosis and timely treatment, and can distinguish different disease types, thereby providing scientific basis for accurate treatment. On the other hand, the characteristics of the thompson deprivation index, the physical activity level, the healthy diet index and the like of the obstructive sleep apnea crowd are studied in a form of a table, so that the physical condition and the daily activity habit of a patient can be more intuitively known, a personalized treatment scheme is formulated, and the treatment scheme is adjusted in time and the health condition of the patient is predicted. In addition, it is helpful to deeply investigate the pathogenesis of the disease and find new therapeutic methods.
Furthermore, in this embodiment, other factors are analyzed and studied in a table form, which is helpful for improving the cognitive level of the disease, making a more effective treatment scheme, and only one optional condition of this embodiment, the specific analysis method can be adjusted according to the actual requirement, so that the pathogenesis of obstructive sleep apnea can be better understood, and a more effective treatment scheme can be made.
S3, analyzing influence relations between different amino acid levels and obstructive sleep apnea risks based on blood plasma amino acid levels, and selecting a plurality of amino acids as scoring parameters according to the influence relations, wherein the specific implementation steps and related contents are as follows:
first, the correlation of plasma amino acid levels with the risk of obstructive sleep apnea is analyzed, in this example the correlation includes, but is not limited to, positive correlation, negative correlation, and no significant correlation;
Analysis of the correlation of plasma amino acid levels with risk of obstructive sleep apnea may provide a better understanding of the pathogenesis of obstructive sleep apnea, if an amino acid is found to be positively or negatively correlated with the risk of obstructive sleep apnea, the amino acid may be a therapeutic target or a prophylactic measure for the disease. On the other hand, the correlation between the blood plasma amino acid level and the obstructive sleep apnea risk is analyzed, the risk probability of illness can be predicted, the high-risk population can be identified in early stage, and more positive preventive measures are adopted based on the high-risk population, so that the occurrence rate of obstructive sleep apnea is reduced.
The positive correlation, the negative correlation and no obvious correlation can comprehensively understand the relationship between the blood plasma amino acid level and the risk of obstructive sleep apnea, and is helpful for deeply understanding the pathogenesis of diseases, and provides more clues for subsequent research, so that more positive preventive measures are adopted.
Furthermore, the classification standard and specific content of the correlation in this embodiment are only an optional condition of this embodiment, and the specific content of the correlation can be optimized according to the actual situation, which is helpful for adjusting the treatment scheme and promoting the exploration and research of the relationship between the disease and the blood plasma amino acid level.
Then, according to the correlation relationship, the influence relationship of different amino acid levels on the risk of obstructive sleep apnea can be further analyzed.
From the existing findings and follow-up data, elevated levels of tyrosine, isoleucine, valine and phenylalanine in plasma are significantly associated with the risk of obstructive sleep apnea. Among these, elevated levels of tyrosine, isoleucine, valine and phenylalanine lead to a corresponding increase in the risk of occurrence of obstructive sleep apnea. I.e. the above mentioned elevation of plasma amino acid levels is a risk factor for the occurrence of obstructive sleep apnea.
In particular, there is a significant positive correlation between increased levels of tyrosine, isoleucine, valine and phenylalanine in plasma and the risk of occurrence of obstructive sleep apnea. I.e. the risk of the individual suffering from obstructive sleep apnea increases accordingly.
Studies have also found that elevated levels of histidine, glutamine and glycine in plasma are significantly associated with a reduced risk of obstructive sleep apnea. In particular, increased levels of histidine, glutamine and glycine may reduce the risk factor of an individual for obstructive sleep apnea, thereby protecting the individual. Based on this, a new view and research direction are provided for the etiology and prevention of obstructive sleep apnea.
Based on the research results and the correlation rules, the complex correlation between the blood plasma amino acid level and the occurrence risk of obstructive sleep apnea is disclosed, and the analysis method is beneficial to ensuring the accuracy and reliability of the analysis results, helping to understand the pathogenesis of obstructive sleep apnea deeply, and providing a new view for the treatment strategy.
Finally, selecting a plurality of amino acids as scoring parameters according to the influence relation, wherein the scoring parameters comprise the following specific contents:
Based on the influence relationship of different amino acid levels on the risk of the new obstructive sleep apnea, tyrosine, isoleucine, valine and phenylalanine respectively have positive correlation with the risk of the obstructive sleep apnea; histidine, glutamine and glycine have a negative correlation with the risk of occurrence of obstructive sleep apnea, respectively; leucine and alanine were not significantly associated with the risk of obstructive sleep apnea occurrence, respectively.
Thus, histidine is selected as a first scoring parameter, tyrosine is selected as a second scoring parameter, isoleucine is selected as a third scoring parameter, valine is selected as a fourth scoring parameter, glutamine is selected as a fifth scoring parameter, glycine is selected as a sixth scoring parameter, and phenylalanine is selected as a seventh scoring parameter according to the influence relation.
In the embodiment, the different amino acids are known and analyzed, so that the relationship between the different amino acid levels and the obstructive sleep apnea can be better known, and positive measures are taken to prevent the occurrence of diseases and reduce the occurrence rate of the diseases.
S4, analyzing the effect of different scoring parameters on the risk of obstructive sleep apnea according to the influence relation, wherein the specific implementation steps and related contents are as follows:
in order to make the influence relationship of different amino acids more comparable, the amino acid level is quartered in this embodiment, based on which the accuracy of predicting obstructive sleep apnea can be improved.
In the implementation, an analysis rule of obstructive sleep apnea risk is set according to the influence relation; and then obtaining the effect of different amino acid levels on the risk of obstructive sleep apnea based on the analysis rules and the influence relation.
Tyrosine, isoleucine, valine, phenylalanine, histidine, glutamine and glycine are selected as key scoring parameters according to analysis, and specific analysis is carried out on the key scoring parameters, and corresponding analysis rules are set.
Among them, tyrosine, isoleucine, valine and phenylalanine have a positive correlation with the risk of occurrence of obstructive sleep apnea. It is stated that the above-mentioned amino acid levels are elevated in the body and the risk of occurrence of obstructive sleep apnea is correspondingly increased, and when tyrosine, isoleucine, valine and phenylalanine are elevated or in an abnormal range, the occurrence probability of obstructive sleep apnea is promoted, and the corresponding analysis rules are set to a state of increasing risk factors of individuals suffering from the obstructive sleep apnea. Since the changes in the amino acids described above are associated with the pathogenesis of obstructive sleep apnea, they affect neurotransmitter synthesis and metabolism and thus the function of the sleep respiratory center, resulting in the occurrence of obstructive sleep apnea.
Histidine, glutamine and glycine have a negative correlation with the risk of obstructive sleep apnea occurrence. It is stated that the above amino acid levels are elevated in the body and the risk of obstructive sleep apnea may be reduced. When histidine, glutamine and glycine are elevated or within normal ranges, the probability of occurrence of obstructive sleep apnea is reduced, and the corresponding analysis rules set the risk factor reduction state of the individual suffering from the disease at that time. The amino acid has the effects of protecting cells, promoting repair, regulating immune function and the like in vivo, and can prevent or relieve the occurrence and the severity of obstructive sleep apnea to a certain extent, thereby inhibiting the generation of free radicals and protecting cells from oxidative damage.
Based on this analysis rule, it is set that tyrosine, isoleucine, valine and phenylalanine promote the occurrence of obstructive sleep apnea, and if the level of the relevant amino acid in serum does not fall within a safe level range, it is considered that the risk of occurrence of obstructive sleep apnea is increased, and the physical condition of the individual is reduced. Wherein histidine, glutamine and glycine inhibit the occurrence of obstructive sleep apnea, and if the level of the relevant amino acids in the serum is within a safe level interval, it is considered that the risk of occurrence of obstructive sleep apnea is reduced, and the physical condition of the individual is scored.
Furthermore, an analysis rule may be set for each amino acid parameter and determined based on their strength of correlation with the risk of obstructive sleep apnea. However, in this embodiment, the positive correlation group and the negative correlation group are obtained by classifying the plurality of amino acids according to the correlation, and addition and subtraction calculation is performed on the individual physical condition, based on which the relief measures and treatment schemes can be determined more quickly, and for the patient with higher positive correlation group amino acid level, measures can be taken to reduce the level of the relevant amino acid or suppress the effect thereof, so as to reduce the risk of obstructive sleep apnea, or increase the intake of the negative correlation group amino acid, or further reduce the intake of the positive correlation group amino acid, which may help to reduce the risk of obstructive sleep apnea.
Then, for different amino acid levels, the number of amino acid samples, the number and proportion of obstructive sleep apnea patients and the risk factors of related amino acids, and in this embodiment, according to the predicted data and the actual situation, the confidence interval of the analysis rule is set to be ninety five percent, wherein the ninety five percent confidence interval refers to that the probability that the actual value of the predicted overall data will fall within the interval of the measurement result.
The analysis rules of this embodiment analyze different amino acid levels, the number of amino acid samples, the number and proportion of patients suffering from obstructive sleep apnea and the risk factors of related amino acids, so that the relationship between the amino acids and obstructive sleep apnea can be understood more deeply, the pathogenesis of obstructive sleep apnea can be understood better, and clues are provided for developing new treatment methods.
Dividing the amino acid level of the scoring parameter into four equal parts by combining the scoring parameter and the action effect; the horizontal interval of each scoring parameter is set according to the result of the amino acid level quartering, and the specific content is as follows:
In order to explore the influence relation between different amino acids and the occurrence risk of obstructive sleep apnea, in this embodiment, the amino acid levels of the scoring parameters are quartered, so that the action situation between the different amino acid levels and obstructive sleep apnea can be known in more detail, and the influence mechanism of obstructive sleep apnea can be understood better, so that measures are taken to adjust the levels of the relevant amino acids or inhibit the action thereof, so as to reduce the occurrence risk of obstructive sleep apnea.
The amino acid levels are quartered in the examples and the effects of different amino acid levels on the risk of developing obstructive sleep apnea are analyzed, including but not limited to, the halving of different amino acid levels, the number and proportion of obstructive sleep apnea sufferers, and the risk factors for the relevant amino acids.
In an alternative embodiment, the amino acid levels of the seven scoring parameters are quartered as follows:
wherein Quartile denotes an equal-level grouping, quartile 2 denotes a equal-level grouping, quartile 3 denotes a three-level grouping, quartile denotes a four-level grouping, and the amino acid level four of the seven scoring parameters are as follows:
four-split histidine ：Quartile 1(<0.058 mmol/L)、Quartile 2(0.058 mmol/L-<0.064 mmol/L)、Quartile 3(0.064 mmol/L-<0.070 mmol/L)、Quartile 4(≥0.070 mmol/L);
Four-split tyrosine case ：Quartile 1(<0.052 mmol/L)、Quartile 2(0.052 mmol/L-<0.060 mmol/L)、Quartile 3(0.060 mmol/L-<0.069 mmol/L)、Quartile 4(≥0.069 mmol/L);
Four-aliquoting of isoleucine ：Quartile 1(<0.038 mmol/L)、Quartile 2(0.038 mmol/L -<0.047 mmol/L)、Quartile 3(0.047 mmol/L -<0.058 mmol/L)、Quartile 4(≥0.058 mmol/L);
Case of valine quartering ：Quartile 1(<0.17 mmol/L)、Quartile 2(0.17 mmol/L -<0.20 mmol/L)、Quartile 3(0.20 mmol/L -<0.23 mmol/L)、Quartile 4(≥0.23 mmol/L);
Four-split glutamine ：Quartile 1(<0.48 mmol/L)、Quartile 2(0.48 mmol/L -<0.53 mmol/L)、Quartile 3(0.53 mmol/L -<0.58 mmol/L)、Quartile 4(≥0.58 mmol/L);
Four-split glycine case ：Quartile 1(<0.12 mmol/L)、Quartile 2(0.12 mmol/L -<0.15 mmol/L)、Quartile 3(0.15 mmol/L -<0.19 mmol/L)、Quartile 4(≥0.19 mmol/L);
Phenylalanine tetrad case ：Quartile 1(<0.038 mmol/L)、Quartile 2(0.038 mmol/L -<0.044 mmol/L)、Quartile 3(0.044 mmol/L -<0.051 mmol/L)、Quartile 4(≥0.051 mmol/L).
To ensure the accuracy of the analysis results of the risk of occurrence of obstructive sleep apnea at different amino acid levels, two prediction groups are set for risk ratio testing in this embodiment, wherein the first prediction group: age, gender was adjusted, second prediction group: the composition can be used for regulating age, sex, race, research center, thompson deprivation index, smoking, drinking, physical activity, health diet index, obesity, asthma, hypertension, diabetes and hyperlipidemia.
The second prediction group performs more comprehensive risk assessment relative to the first prediction group, and more potential influence factors are included, so that the risk of occurrence of obstructive sleep apnea in specific people can be predicted more accurately.
Based on the results of the amino acid level quarters, the effect of different conditions on the risk of occurrence of obstructive sleep apnea was obtained, see table 2.
/>
/>
TABLE 2 Effect of different amino acid levels on the risk of obstructive sleep apnea
Based on this, it is clear that an increase in plasma tyrosine, isoleucine, valine and phenylalanine levels is significantly associated with an increase in the risk of obstructive sleep apnea, please refer to fig. 2, as tyrosine increases, the risk of obstructive sleep apnea increases with an increase in tyrosine, as seen in table 2, with an increase in the risk of sleep apnea by 11% per standard deviation, the risk ratio being 1.11, with a corresponding 95% confidence interval of 1.06-1.16.
Based on this, in an alternative embodiment, please refer to fig. 3, as the risk of obstructive sleep apnea increases with increasing isoleucine, it can be seen from table 2 that each time isoleucine increases by one standard deviation, the risk of obstructive sleep apnea increases by 6%, the risk ratio is 1.06, and the corresponding 95% confidence interval is 1.01-1.12.
Based on this, in another alternative embodiment, please refer to fig. 4, as valine increases the risk of obstructive sleep apnea increases, as can be seen from table 2, each time valine increases by one standard deviation resistance, the risk of occurrence of obstructive sleep apnea increases by 7%, the risk ratio is 1.07, and the corresponding 95% confidence interval is 1.02-1.12.
Based on this, in another alternative embodiment, please refer to fig. 5, as the risk of obstructive sleep apnea increases with increasing phenylalanine, it can be seen from table 2 that each time phenylalanine increases by one standard deviation, the risk of obstructive sleep apnea increases by 7%, the risk ratio is 1.07, and the corresponding 95% confidence interval is 1.02-1.11.
In particular, the increase of the blood plasma amino acid level can be a risk factor for the occurrence of obstructive sleep apnea, and tyrosine, isoleucine, valine and phenylalanine respectively have a significant positive correlation with the occurrence risk of obstructive sleep apnea.
On the other hand, studies have also found that elevated plasma histidine, glutamine and glycine levels are significantly associated with a reduced risk of obstructive sleep apnea.
Based on this, in another alternative embodiment, please refer to fig. 6, as the histidine increases, the risk of obstructive sleep apnea decreases, as can be seen from table 2, each time histidine increases by one standard deviation, the risk of obstructive sleep apnea decreases by 7%, the risk ratio is 0.93, and the corresponding 95% confidence interval is 0.88-0.98.
Based on this, in another alternative embodiment, please refer to fig. 7, the risk of obstructive sleep apnea decreases with increasing glutamine, as can be seen from table 2, each time glutamine increases by one standard deviation, the risk of obstructive sleep apnea decreases by 6%, the risk ratio is 0.94, and the corresponding 95% confidence interval is 0.89-0.99.
Based on this, in another alternative embodiment, please refer to fig. 8, as glycine increases, the risk of obstructive sleep apnea decreases, as can be seen from table 2, each time glycine increases by one standard deviation, the risk of occurrence of obstructive sleep apnea decreases by 14%, the risk ratio is 0.86, and the corresponding 95% confidence interval is 0.80-0.92.
Based on the amino acid effect relationship, it is known that the increase of the blood plasma amino acid level may be a protecting factor for the occurrence of obstructive sleep apnea, and histidine, glutamine and glycine are respectively in a significant negative correlation with the occurrence risk of obstructive sleep apnea.
Furthermore, as can be seen from table 2, for each increase in plasma leucine levels with one standard deviation, the risk ratio for obstructive sleep apnea is 1.04, with a corresponding 95% confidence interval of 0.99-1.10; for every increase in plasma alanine levels of one standard deviation, the risk ratio for obstructive sleep apnea is 1.00, with a corresponding 95% confidence interval of 0.95-1.05. That is, it is meant that changes in plasma leucine and alanine levels are not significantly associated with the risk of obstructive sleep apnea. Based on this, it is clear that changes in plasma leucine and alanine levels may not be a risk or protective factor for the occurrence of obstructive sleep apnea, leucine and alanine, respectively, have no significant correlation with the risk of obstructive sleep apnea.
In this embodiment, the effect of different amino acid levels on the risk of obstructive sleep apnea is obtained based on the analysis rules and the correlation of different amino acids to the risk of obstructive sleep apnea. The relation between the amino acid and the obstructive sleep apnea can be further understood, and the reliability of the prediction result is improved.
Furthermore, in this embodiment, the effect of different amino acid levels on the risk of obstructive sleep apnea is analyzed, which is only an optional condition of this embodiment, and the specific analysis method can be adjusted according to the actual situation, so as to help to predict the illness state more accurately.
And S5, setting a horizontal interval of a scoring parameter according to the action effect, scoring the individual amino acid level based on the horizontal interval, and predicting the occurrence risk of the individual obstructive sleep apnea. In the present embodiment, first, the horizontal section of each scoring parameter is set based on table 2, and its implementation is as follows:
The patient's severity of illness and risk level can be more accurately assessed based on the level interval of the scoring parameter. The horizontal intervals of each scoring parameter are set to analyze different scoring parameters based on the analysis, so that the illness state and risk factors of a patient can be more comprehensively known, on the other hand, the risk coefficient of the patient possibly suffering from the illness can be more accurately predicted by carrying out disease risk prediction according to the horizontal intervals of each scoring parameter, and the risk prediction is carried out according to the horizontal intervals of a plurality of scoring parameters, so that the prediction result is more reliable than that of a single parameter.
Please refer to table 3, whereinA safety level interval representing a scoring parameter, i.e. a safety level range, at which the risk of an individual for obstructive sleep apnea will be significantly reduced; /(I)The risk level interval representing the scoring parameter, i.e. the non-safety level range, will be at a significantly increased risk of obstructive sleep apnea in the individual.
Still further, based on table 2, it can be seen that: safe level interval of histidineComprising the following steps: quartile 3 (0.064 mmol/L- <0.070 mmol/L), quartile 4 (. Gtoreq.0.070 mmol/L); safe horizontal interval of tyrosineComprising the following steps: quartile 1 (< 0.052 mmol/L), quartile 2 (0.052 mmol/L- <0.060 mmol/L); safe level interval of isoleucine/>Comprising the following steps: quartile 1 (< 0.038 mmol/L), quartile 2 (0.038 mmol/L- <0.047 mmol/L); safe level interval of valine/>Comprising the following steps: quartile 1 (< 0.17 mmol/L), quartile 2 (0.17 mmol/L- <0.20 mmol/L); safe level interval of glutamine/>Comprising the following steps: quartile 3 (0.53 mmol/L- <0.58 mmol/L), quartile 4 (. Gtoreq.0.58 mmol/L); safe level interval of glycine/>Comprising the following steps: quartile 3 (0.15 mmol/L- <0.19 mmol/L), quartile 4 (. Gtoreq.0.19 mmol/L); safe level interval of phenylalanine/>Comprising the following steps: quartile 1 (< 0.038 mmol/L), quartile 2 (0.038 mmol/L- <0.044 mmol/L), see Table 2. /(I)
TABLE 3 horizontal interval forms of scoring parameters amino acids
In this embodiment, according to the scoring parameters and the corresponding effects, the horizontal intervals of the scoring parameters are set, and the water intervals of the scoring parameters are divided into a safe horizontal interval (Quartile A) and a dangerous horizontal interval (Quartile B), so that the risk level of obstructive sleep apnea of an individual can be clarified, the illness state can be known more accurately, and corresponding preventive and therapeutic measures can be taken.
Furthermore, in this embodiment, the setting of the horizontal interval of each scoring parameter is only an optional condition of this embodiment by combining the scoring parameters, the effects of different amino acids and the quartering results, and the setting of the horizontal interval of the scoring parameters can be changed and adjusted according to the prediction requirements, so that the illness state can be predicted more accurately, and the risk degree of the obstructive sleep apnea of the individual can be clarified.
Then, scoring the occurrence risk of the individual obstructive sleep apnea based on the horizontal interval of each scoring parameter, and predicting the occurrence risk of the obstructive sleep apnea, wherein the specific implementation content is as follows:
firstly, setting a diversity scoring model according to scoring parameters and corresponding horizontal intervals;
the diversity scoring model satisfies the following relationship:
Wherein, Representing diversity scoring results, n representing the number of scoring parameters,/>And the scoring results of the scoring parameters are represented.
The scoring parameters in this embodiment include histidine, tyrosine, isoleucine, valine, glutamine, glycine, phenylalanine, if histidine is in the safe level interval) I.e. scoring parameters at this time/>In the standard-reaching state, the risk of the individual to suffer from obstructive sleep apnea is obviously reduced, and the scoring parameters reach the standard and/>; Conversely if histidine is in the dangerous level interval (/ >)) I.e. scoring parameters at this time/>In a non-standard state, the risk of obstructive sleep apnea of the individual is increased significantly, and the scoring parameter is not marked/>。
The score conditions of different scoring parameters are obtained according to the diversity scoring model, quantitative evaluation can be carried out on the illness state and the risk of the patient, more accurate and objective decision basis can be provided, and the accuracy of diagnosis and treatment can be improved. Then, scoring results of each scoring parameter are obtained according to the diversity scoring model, and the specific calculation content is as follows: in the diversity scoring model, n represents the number of scoring parameters, where n=7. In an alternative embodiment, if histidine is not less than 0.064mmol/L, it is indicated that histidine is in the safe level interval (Quartile A), i.e., the scoring parameter is in a state of up-to-standard, where the risk of obstructive sleep apnea in the individual will be significantly reduced, then the result of the histidine scoring; Conversely, if histidine is less than 0.064mmol/L, the result indicates that histidine is in a dangerous level interval (Quartile B), namely the scoring parameter belongs to a non-standard state, at the moment, the risk of the individual to suffer from obstructive sleep apnea is increased remarkably, and at the moment, the scoring result of histidine/>；
In an alternative embodiment, if tyrosine <0.060mmol/L, it is indicated that tyrosine is in the safe level interval (Quartile A), i.e. the scoring parameter is in a state of up to standard, where the risk of obstructive sleep apnea in the individual will be significantly reduced, then the scoring result of tyrosine; Otherwise, if the tyrosine is more than or equal to 0.060mmol/L, the tyrosine is shown in a dangerous level interval (Quartile B), namely the scoring parameter belongs to a non-standard state, at the moment, the risk of the individual to suffer from obstructive sleep apnea is obviously increased, and at the moment, the scoring result/>；
In an alternative embodiment, if isoleucine is <0.047mmol/L, then it is indicated that isoleucine is in the safe level interval (Quartile A), i.e., the scoring parameter is in a state of compliance, where the individual's risk of developing obstructive sleep apnea will be significantly reduced, then the result of the isoleucine scoring; If the isoleucine is more than or equal to 0.047mmol/L, the isoleucine is in a dangerous level interval (Quartile B), namely the scoring parameter belongs to a non-standard state, the risk of the individual to suffer from obstructive sleep apnea is obviously increased, and the scoring result of the isoleucine；
In an alternative embodiment, if valine is <0.20mmol/L, then valine is scored in the safe level interval (Quartile A), i.e., the scoring parameter is in a standard condition, where the individual's risk of obstructive sleep apnea is significantly reduced, then valine is scored; Otherwise, if valine is more than or equal to 0.20mmol/L, the valine is in a dangerous level interval (Quartile B), namely the scoring parameter belongs to a non-standard state, the risk of obstructive sleep apnea of the individual is obviously increased, and the scoring result/>, of the valine；
In an alternative embodiment, if glutamine is greater than or equal to 0.53mmol/L, then the result of the glutamine scoring is that the glutamine is in a safe level interval (Quartile A), i.e., the scoring parameter is in a state of being up to standard, where the individual's risk of obstructive sleep apnea will be significantly reduced; Conversely, if glutamine is less than 0.53mmol/L, then the result of glutamine scoring is that the glutamine is in a dangerous level interval (Quartile B), i.e. the scoring parameter is in a substandard state, at which time the risk of obstructive sleep apnea in the individual will be significantly increased；
In another alternative embodiment, if glycine is not less than 0.15mmol/L, it is indicated that glycine is in the safe level interval (Quartile A), i.e., the scoring parameter is in the up-to-standard state, at which time the risk of obstructive sleep apnea in the individual will be significantly reduced, and the scoring result of glycine; If glycine is less than 0.15mmol/L, the method indicates that glycine is in a dangerous level interval (Quartile B), namely the scoring parameter belongs to a non-standard state, the risk of obstructive sleep apnea of an individual is obviously increased, and the scoring result of glycine/>；
In an alternative embodiment, if phenylalanine <0.044mmol/L, it is indicated that phenylalanine is in the safe level interval (Quartile A), i.e. the scoring parameter is in a state of up to standard, where the risk of obstructive sleep apnea in the individual will be significantly reduced, then the result of the phenylalanine scoring; Otherwise, if phenylalanine is more than or equal to 0.044mmol/L, the phenylalanine is in a dangerous level interval (Quartile B), namely the scoring parameter belongs to a non-standard state, the risk of the individual to suffer from obstructive sleep apnea is obviously increased, and the scoring result of the phenylalanine。
Finally, predicting the occurrence risk of the individual obstructive sleep apnea according to the scoring result of each scoring parameter, wherein the specific calculation content is as follows:
In this embodiment, the root sums the scoring results of seven amino acids, and predicts the occurrence risk of obstructive sleep apnea of the individual by using the total number of scoring parameters, and the specific implementation method is that if the scoring parameters are 1 score in a safe level interval and 0 score in a dangerous level interval, the total number of the final scoring parameters is 0 score at the minimum and 7 score at the maximum based on the score, and the ammonia diversity scoring rule of the embodiment considers both the safe level and the diversity and the generalization of the amino acid types.
In an alternative embodiment, the diversity score results for each scoring parameter are summed, and if the amino acid averages for the seven scoring parameters are within a safe level interval, then the amino acid diversity score results=1+1+1+1+1+1+1=7：
In another alternative embodiment, the diversity score results for each scoring parameter are summed, and if the amino acid averages for the seven scoring parameters are not within the safe level interval, the amino acid diversity score results=0+0+0+0+0+0=0. Referring to table 4, the scoring results are specifically presented, wherein the scoring results include 0-7 points for a total of eight points, see table 4.
| Amino acid diversity scoring results | Sample size | Case of cases | Model 1: risk ratio (95% confidence interval) | Model 2: risk ratio (95% confidence interval) |
| Every one minute of increase | 116539 | 1655 | 0.76(0.74,0.79) | 0.89(0.86,0.92) |
| 0 | 3445 | 127 | Ref | Ref |
| 1 | 10405 | 298 | 0.78(0.63,0.96) | 0.86(0.70,1.07) |
| 2 | 19227 | 383 | 0.55(0.45,0.67) | 0.72(0.59,0.89) |
| 3 | 25158 | 343 | 0.39(0.32,0.48) | 0.61(0.50,0.76) |
| 4 | 24561 | 258 | 0.32(0.26,0.39) | 0.56(0.45,0.70) |
| 5 | 20114 | 161 | 0.26(0.21,0.33) | 0.55(0.43,0.71) |
| 6 | 10687 | 70 | 0.22(0.16,0.29) | 0.52(0.38,0.71) |
| 7 | 2942 | 15 | 0.17(0.10,0.28) | 0.42(0.24,0.74) |
Table 4 scoring results table for seven amino acids
Based on table 4 and fig. 9, the risk ratio of new obstructive sleep apnea is 0.89 (95% confidence interval is 0.86-0.92) for each score increase of the amino acid diversity model. The amino acid diversity scoring result can be used as an effective prediction index, is beneficial to rapidly and accurately evaluating the risk probability of the occurrence of obstructive sleep apnea of a patient, can more comprehensively evaluate the risk condition of the patient, and provides personalized preventive and therapeutic advice. Meanwhile, the applicability and prediction accuracy of the amino acid diversity scores in different crowds can be further evaluated so as to promote the application of the amino acid diversity scores in clinical practice.
In this example, seven specific amino acids include: histidine, tyrosine, isoleucine, valine, glutamine, glycine and phenylalanine, and different horizontal intervals are set to explore the relationship between different amino acids and the occurrence risk of obstructive sleep apnea, so that the diversity and the comprehensiveness of the amino acids can be comprehensively reflected, and the method has important significance for evaluating the risk of obstructive sleep apnea.
The method for predicting the occurrence risk of the obstructive sleep apnea, which predicts the risk of the new obstructive sleep apnea through amino acid, reveals the influence relation and the action effect between the amino acid and the obstructive sleep apnea, has important clinical application value and public health value, and can provide more accurate diagnosis, treatment and health management advice for patients, thereby improving the life quality and the overall health condition of the patients.
Based on this it is further explored how the different amino acids and their biological activities influence the occurrence and development of obstructive sleep apnea to reveal the underlying pathophysiological mechanisms. In addition, the applicability and prediction accuracy of amino acid diversity scores in different populations can be evaluated to facilitate their application and popularization in clinical practice. Thereby making a targeted health promotion plan and a prevention strategy, reducing the incidence rate of obstructive sleep apnea and improving the public health level and life quality.
Further, as shown in fig. 10, in an alternative embodiment, the system for predicting the risk of occurrence of obstructive sleep apnea further comprises an input device, an output device, and a processor, wherein the input device, the processor, the memory, and the output device are connected to each other to implement information interaction and data processing.
In this embodiment, the input device is used to provide input related data or instructions to the present system. In a system for predicting the risk of occurrence of obstructive sleep apnea, the input device may include a keyboard, a mouse, a touch screen, or other common human-computer interaction interface device. Through the input device, a doctor or researcher can input characteristic gene expression data, related clinical information or other necessary input parameters of the person to be evaluated.
The processor is a core component of the system and is responsible for executing computer program instructions for data processing and analysis. In a system for predicting the risk of occurrence of obstructive sleep apnea, a processor calculates the degree of risk of obstructive sleep apnea of a subject by running a preprogrammed algorithm and model to analyze and interpret the input amino acids. The processor may be a Central Processing Unit (CPU), a Graphics Processor (GPU), or other specialized processing unit.
The memory is used for storing computer programs, data and parameters required by the system. It may include Random Access Memory (RAM) for temporary data storage and processing, and persistent storage (e.g., hard disk or solid state disk) for long-term storage and retention of data. In a system for predicting the risk of occurrence of obstructive sleep apnea, the memory may store a high specific amino acid set, a characteristic amino acid-related prediction model, a predictive analysis result, a characteristic amino acid score result of a subject, and the like.
The output device is used for presenting the results of system processing and analysis to a user or an external device. In a system for predicting the risk of occurrence of obstructive sleep apnea, the output device may be a display, a printer, a diagramming device, or the like. Through the output device, the system may present the predictive evaluation results, such as a predictive score rating or other relevant information. These results may be referenced by a physician, researcher or patient to aid decision making and communication.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention, and are intended to be included within the scope of the appended claims and description.
Claims (5)
1. A system for predicting the risk of occurrence of obstructive sleep apnea, the system comprising a computer readable storage medium, wherein the computer readable storage medium stores a computer program comprising program instructions that when executed by a processor cause the processor to perform the steps of:
Acquiring predictive data of the risk of occurrence of obstructive sleep apnea, the predictive data being derived from a population not diagnosed with obstructive sleep apnea;
performing high-throughput metabolic biomarker analysis on the predicted data to obtain plasma amino acid levels;
Analyzing influence relations between different amino acid levels and obstructive sleep apnea risks based on the plasma amino acid levels, and selecting a plurality of amino acids as scoring parameters according to the influence relations;
Analyzing the effect of the scoring parameter on the risk of obstructive sleep apnea according to the influence relation;
Setting a horizontal interval of a scoring parameter according to the action effect, scoring the occurrence risk of the obstructive sleep apnea of the individual based on the horizontal interval, and predicting the occurrence risk of the obstructive sleep apnea;
and selecting a plurality of amino acids as scoring parameters according to the influence relation, wherein the scoring parameters comprise the following steps:
Selecting histidine as a first scoring parameter according to the influence relation;
tyrosine is selected as a second scoring parameter according to the influence relation;
selecting isoleucine as a third scoring parameter according to the influence relationship;
valine is selected as a fourth scoring parameter according to the influence relation;
Selecting glutamine as a fifth scoring parameter according to the influence relation;
Glycine is selected as a sixth scoring parameter according to the influence relation;
selecting phenylalanine as a seventh scoring parameter according to the influence relation;
the setting of the horizontal interval of the scoring parameter according to the action effect comprises the following steps:
Quartering the amino acid level of the scoring parameter in combination with the scoring parameter and the effect;
setting a horizontal interval of each scoring parameter according to the amino acid level quartering result;
Scoring the occurrence risk of the individual obstructive sleep apnea based on the horizontal interval and predicting the occurrence risk of the obstructive sleep apnea, wherein the method comprises the following steps of:
Obtaining scoring results of each scoring parameter according to the horizontal interval and the action effect;
predicting the occurrence risk of the individual obstructive sleep apnea according to the scoring result;
The scoring result of each scoring parameter is obtained according to the horizontal interval and the action effect, and the method comprises the following steps:
setting a diversity scoring model according to the scoring parameters and the horizontal interval;
and obtaining the scoring result of each scoring parameter according to the diversity scoring model.
2. The system for predicting risk of occurrence of obstructive sleep apnea according to claim 1, wherein said analyzing the influence relationship of different amino acid levels to the risk of obstructive sleep apnea based on said plasma amino acid levels comprises:
Analyzing the plasma amino acid level for a correlation with a risk of obstructive sleep apnea, the correlation comprising a positive correlation, a negative correlation, and no significant correlation;
And analyzing the influence relation of different amino acid levels on the risk of obstructive sleep apnea according to the correlation.
3. The system for predicting risk of occurrence of obstructive sleep apnea of claim 1, wherein said analyzing the effect of said scoring parameter on risk of obstructive sleep apnea based on said impact relationship comprises:
setting analysis rules of obstructive sleep apnea risks according to the influence relation;
And obtaining the effect of different amino acid levels on the risk of obstructive sleep apnea based on the analysis rule and the influence relation.
4. The system for predicting risk of occurrence of obstructive sleep apnea of claim 1, wherein the diversity scoring model satisfies the relationship:
，
Wherein, Representing diversity scoring results, n representing the number of scoring parameters,/>And the scoring results of the scoring parameters are represented.
5. The system for predicting risk of occurrence of obstructive sleep apnea of claim 4, wherein the diversity scoring model is whereinComprising the following steps:
the scoring result of the parameter is marked as 1 if the scoring parameter is not marked as 0;
A scoring result representing a first scoring parameter, which is qualified if the scoring result meets the safety level interval of histidine ；
A scoring result representing a second scoring parameter, which is qualified if the scoring parameter meets the safety level interval of tyrosine；
A scoring result representing a third scoring parameter that meets/>, if the score meets the safety level interval of isoleucine；
A scoring result representing a fourth scoring parameter which is up to standard if the score meets the valine safety level interval；
A scoring result representing a fifth scoring parameter, which meets the safety level interval of glutamine and meets/>；
A scoring result representing a sixth scoring parameter, which is qualified if the safety level interval of glycine is met；
A scoring result representing a seventh scoring parameter, which meets the safety level interval of phenylalanine and meets/>。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311686767.XA CN117747100B (en) | 2023-12-11 | 2023-12-11 | System for predicting occurrence risk of obstructive sleep apnea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311686767.XA CN117747100B (en) | 2023-12-11 | 2023-12-11 | System for predicting occurrence risk of obstructive sleep apnea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117747100A CN117747100A (en) | 2024-03-22 |
| CN117747100B true CN117747100B (en) | 2024-05-14 |
Family
ID=90258526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311686767.XA Active CN117747100B (en) | 2023-12-11 | 2023-12-11 | System for predicting occurrence risk of obstructive sleep apnea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117747100B (en) |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106073722A (en) * | 2016-08-30 | 2016-11-09 | 孟玲 | Health analysis system for monitoring sleep apnea syndrome |
| WO2020027392A1 (en) * | 2018-08-01 | 2020-02-06 | 서울대학교병원 | Method for generating sleep apnea prediction model and method for predicting sleep apnea by using same model |
| WO2020197153A1 (en) * | 2019-03-25 | 2020-10-01 | 삼성전자 주식회사 | Electronic device for screening risk of obstructive sleep apnea, and operation method therefor |
| CN112420196A (en) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | Prediction method and system for survival rate of acute myocardial infarction patient within 5 years |
| CN113409944A (en) * | 2021-06-25 | 2021-09-17 | 清华大学深圳国际研究生院 | Obstructive sleep apnea detection method and device based on deep learning |
| CN113488170A (en) * | 2021-07-02 | 2021-10-08 | 温州医科大学 | Method for constructing prediction model of recurrence risk of acute anterior uveitis and related equipment |
| CN113520343A (en) * | 2020-04-17 | 2021-10-22 | 华为技术有限公司 | Sleep risk prediction method and device and terminal equipment |
| WO2022036053A2 (en) * | 2020-08-13 | 2022-02-17 | Mirvie, Inc. | Methods and systems for determining a pregnancy-related state of a subject |
| CN114068021A (en) * | 2021-11-12 | 2022-02-18 | 南京安睡科技有限公司 | Risk factor combination for predicting dementia risk and dementia risk score prediction model constructed by risk factor combination |
| CN114334148A (en) * | 2021-12-27 | 2022-04-12 | 中国人民解放军总医院第二医学中心 | System for assessing risk of post-hepatectomy complications in a subject prior to surgery |
| CN114694845A (en) * | 2022-04-02 | 2022-07-01 | 南方医科大学南方医院 | Glomerular disease prognosis prediction system, device and medium based on clinical and pathological indexes |
| KR20220096373A (en) * | 2020-12-31 | 2022-07-07 | 아주대학교산학협력단 | Appratus and method for predicting sleep apnea risk |
| IL280496A (en) * | 2021-01-28 | 2022-08-01 | Yeda Res & Dev | Machine learning models for predicting laboratory test results |
| KR102451624B1 (en) * | 2021-10-05 | 2022-10-11 | 연세대학교 산학협력단 | Cardiovascular disease risk analysis system and method considering sleep apnea factors |
| CN115527676A (en) * | 2022-10-13 | 2022-12-27 | 四川大学华西医院 | OSA (OSA) morbidity risk assessment method and system |
| CN115840050A (en) * | 2021-09-18 | 2023-03-24 | 四川大学 | Application of reagent for detecting metabolic marker in preparation of sleep disorder screening or diagnosis product |
| CN116798632A (en) * | 2023-07-13 | 2023-09-22 | 山东第一医科大学附属省立医院(山东省立医院) | Stomach cancer molecular typing and prognosis prediction model construction method based on metabolic genes and application |
| CN117012390A (en) * | 2023-08-03 | 2023-11-07 | 遵义医科大学附属医院 | Tubercular meningitis death risk assessment model, construction method, system and device |
| CN117064333A (en) * | 2023-08-01 | 2023-11-17 | 大连市中心医院 | Primary screening device for obstructive sleep apnea hypopnea syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016197053A1 (en) * | 2015-06-05 | 2016-12-08 | Beckman Coulter, Inc. | Obstructive sleep apnea (osa) biomarker panel |
| US20220254461A1 (en) * | 2017-02-09 | 2022-08-11 | Cognoa, Inc. | Machine learning algorithms for data analysis and classification |
-
2023
- 2023-12-11 CN CN202311686767.XA patent/CN117747100B/en active Active
Patent Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106073722A (en) * | 2016-08-30 | 2016-11-09 | 孟玲 | Health analysis system for monitoring sleep apnea syndrome |
| WO2020027392A1 (en) * | 2018-08-01 | 2020-02-06 | 서울대학교병원 | Method for generating sleep apnea prediction model and method for predicting sleep apnea by using same model |
| WO2020197153A1 (en) * | 2019-03-25 | 2020-10-01 | 삼성전자 주식회사 | Electronic device for screening risk of obstructive sleep apnea, and operation method therefor |
| CN113520343A (en) * | 2020-04-17 | 2021-10-22 | 华为技术有限公司 | Sleep risk prediction method and device and terminal equipment |
| WO2022036053A2 (en) * | 2020-08-13 | 2022-02-17 | Mirvie, Inc. | Methods and systems for determining a pregnancy-related state of a subject |
| CN112420196A (en) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | Prediction method and system for survival rate of acute myocardial infarction patient within 5 years |
| KR20220096373A (en) * | 2020-12-31 | 2022-07-07 | 아주대학교산학협력단 | Appratus and method for predicting sleep apnea risk |
| IL280496A (en) * | 2021-01-28 | 2022-08-01 | Yeda Res & Dev | Machine learning models for predicting laboratory test results |
| CN113409944A (en) * | 2021-06-25 | 2021-09-17 | 清华大学深圳国际研究生院 | Obstructive sleep apnea detection method and device based on deep learning |
| CN113488170A (en) * | 2021-07-02 | 2021-10-08 | 温州医科大学 | Method for constructing prediction model of recurrence risk of acute anterior uveitis and related equipment |
| CN115840050A (en) * | 2021-09-18 | 2023-03-24 | 四川大学 | Application of reagent for detecting metabolic marker in preparation of sleep disorder screening or diagnosis product |
| KR102451624B1 (en) * | 2021-10-05 | 2022-10-11 | 연세대학교 산학협력단 | Cardiovascular disease risk analysis system and method considering sleep apnea factors |
| CN114068021A (en) * | 2021-11-12 | 2022-02-18 | 南京安睡科技有限公司 | Risk factor combination for predicting dementia risk and dementia risk score prediction model constructed by risk factor combination |
| CN114334148A (en) * | 2021-12-27 | 2022-04-12 | 中国人民解放军总医院第二医学中心 | System for assessing risk of post-hepatectomy complications in a subject prior to surgery |
| CN114694845A (en) * | 2022-04-02 | 2022-07-01 | 南方医科大学南方医院 | Glomerular disease prognosis prediction system, device and medium based on clinical and pathological indexes |
| CN115527676A (en) * | 2022-10-13 | 2022-12-27 | 四川大学华西医院 | OSA (OSA) morbidity risk assessment method and system |
| CN116798632A (en) * | 2023-07-13 | 2023-09-22 | 山东第一医科大学附属省立医院(山东省立医院) | Stomach cancer molecular typing and prognosis prediction model construction method based on metabolic genes and application |
| CN117064333A (en) * | 2023-08-01 | 2023-11-17 | 大连市中心医院 | Primary screening device for obstructive sleep apnea hypopnea syndrome |
| CN117012390A (en) * | 2023-08-03 | 2023-11-07 | 遵义医科大学附属医院 | Tubercular meningitis death risk assessment model, construction method, system and device |
Non-Patent Citations (12)
| Title |
|---|
| Multimodal Hydrogel-Based Respiratory Monitoring System for Diagnosing Obstructive Sleep Apnea Syndrome;Liu Jing，等;ADVANCED FUNCTIONAL MATERIALS;20220731;第32卷(第40期);1-12 * |
| Relationship of serum 25-hydroxyvitamin D, obesity with new-onset obstructive sleep apnea;Zhang Yuanyuan，等;INTERNATIONAL JOURNAL OF OBESITY;20231119;218-22 * |
| Review of Application of Machine Learning as a Screening Tool for Diagnosis of Obstructive Sleep Apnea;Aiyer Ishan，等;MEDICINA-LITHUANIA;20221122;第58卷(第11期);1-10 * |
| The effect of obstructive sleep apnea on peripheral blood amino acid and biogenic amine metabolome at multiple time points overnight;Kiens Ott，等;SCIENTIFIC REPORTS;20210627;第11卷(第1期);1-10 * |
| The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome;Aksu O，等;JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION;20150422;第38卷(第4期);463-469 * |
| 健康管理对阻塞性睡眠呼吸暂停综合征空勤人员睡眠及疗养满意率的影响分析;厉海燕;许秀娟;;心理月刊;20200225(第04期);69 * |
| 睡眠呼吸暂停的人工智能分析;张少杰，等;生物物理学;20200229;第8卷(第1期);1-17 * |
| 老年阻塞性睡眠呼吸暂停低通气综合征患者冠心病发病风险的调查;林文婷;曾敏;陈积雄;何扬利;蒙绪卿;符秀虹;;中华老年心脑血管病杂志;20201231(第02期);47-49 * |
| 赵家军，彭永德.《***内分泌学 下》.中国科学技术出版社,2021,1439-1440. * |
| 阻塞性睡眠呼吸暂停低通气综合征动物模型大鼠小脑和海马组织中谷氨酸水平的变化;徐轶;李向阳;单琳;;中国医学前沿杂志(电子版);20181220(第12期);31-34 * |
| 阻塞性睡眠呼吸暂停综合征和高血压的相关性;陈晓毅，等;深圳中西医结合杂志;20210615;第31卷(第11期);29-31 * |
| 阻塞性睡眠呼吸暂停综合症的代谢组学和微生物组学标志物综述;张小曼，等;中国睡眠研究会第十四届全国学术年会论文汇编;20220902;1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117747100A (en) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wolff-Hughes et al. | Total activity counts and bouted minutes of moderate-to-vigorous physical activity: relationships with cardiometabolic biomarkers using 2003–2006 NHANES | |
| Rattanachaiwong et al. | Comparison of nutritional screening and diagnostic tools in diagnosis of severe malnutrition in critically ill patients | |
| JP2009535644A (en) | Method and apparatus for identifying disease status using biomarkers | |
| Park et al. | Validity of muscle-to-fat ratio as a predictor of adult metabolic syndrome | |
| Ridwan et al. | Peak expiratory flow rate and sarcopenia risk in older Indonesian people: A nationwide survey | |
| Tan et al. | Associations between perceived stress and BMI and waist circumference in Chinese adults: data from the 2015 China Health and Nutrition Survey | |
| An et al. | Body fat is related to sedentary behavior and light physical activity but not to moderate-vigorous physical activity in type 2 diabetes mellitus | |
| He et al. | Prevalence and factors influencing sarcopenia among community-dwelling older adults using the Asian Working Group for Sarcopenia Definition | |
| Koskela et al. | Longitudinal HRQoL shows divergent trends and identifies constant decliners in asthma and COPD | |
| CN117747100B (en) | System for predicting occurrence risk of obstructive sleep apnea | |
| Ravindran et al. | Three contactless sleep technologies compared with Actigraphy and polysomnography in a heterogeneous Group of Older men and Women in a model of mild sleep disturbance: Sleep laboratory study | |
| Saengmolee et al. | Consumer-grade brain measuring sensor in people with long-term kratom consumption | |
| Jeon et al. | Association of Metabolic Syndrome with COVID-19 in the Republic of Korea | |
| Du et al. | Development of a Practical Screening Tool to Predict Sarcopenia in Patients on Maintenance Hemodialysis | |
| Lee et al. | The association of Sasang constitutional types with metabolic syndrome: a pooled analysis of data from three cohorts | |
| Aggarwal et al. | Validation of a Hindi translation of Mini Asthma Quality of Life Questionnaire in north Indian patients with bronchial asthma | |
| Wei et al. | The relationship between Internet addiction and internalizing problems in overweight/obese adolescents: A moderated mediation model | |
| RU2611900C1 (en) | Method for prediction of risk of type 2 diabetes development | |
| Puig-Navarro et al. | S23. EFFICACY OF COGNITIVE-BEHAVIORAL SOCIAL SKILLS TRAINING IMPROVING SYMPTOMS AND FUNCTIONING IN PATIENTS WITH EARLY-ONSET PSYCHOSIS: A RANDOMIZED CONTROLLED TRAIL | |
| G Ravindran et al. | Three Contactless Sleep Technologies Compared With Actigraphy and Polysomnography in a Heterogeneous Group of Older Men and Women in a Model of Mild Sleep Disturbance: Sleep Laboratory Study | |
| CN117690587A (en) | Pancreatic cancer occurrence risk prediction system based on amino acid and storage medium | |
| Wang et al. | Depression Status and Longitudinal Changes in Serum Uric Acid Concentration in Chinese Adults | |
| CN118098621B (en) | Chinese and western medicine combined disease animal model data acquisition system and processing method thereof | |
| Tousi et al. | Comparison of Nearest Neighbor and Caliper Algorithms in Outcome Propensity Score Matching to Study the Relationship between Type 2 Diabetes and Coronary Artery Disease | |
| Suda et al. | Prediction and predictor elucidation of metabolic syndrome onset among young workers using machine learning techniques: A nationwide study in Japan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |